Skip to main content

Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Completed · Phase 2 · NCT03196427

Conditions: Ulcerative Colitis, Crohn's Disease

At a glance

Research payments reported, 2025
$437,921
U.S. investigators named
11
Sites paid
10
Planned or actual enrollment
59

About the trial

Sponsor
Takeda (with Takeda Development Center Americas, Inc.)
Tested
Vedolizumab (drug)
Dates
Started 2018-07-30; completion 2025-07-17
Results posted
Yes

The purpose of this study is to determine the safety profile of long-term vedolizumab IV treatment in pediatric participants with UC or CD.

From ClinicalTrials.gov, last updated 2026-05-13. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Takeda Pharmaceuticals U.S.A., Inc. reported $437,921 in research payments for this study in 2025 (58 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.